Aprea Therapeutics Inc stock is traded at $0.406, with a volume of 134,967. It is down -0.07% in the last 24 hours and down -30.50% over the past month. Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.
Previous Close:
$0.4063
Open:
$0.3954
24h Volume:
134,967
Relative Volume:
0.54
Market Cap:
$5.76M
Revenue:
$123.30K
Net Income/Loss:
-$11.95M
P/E Ratio:
-
EPS:
-$1.54
Net Cash Flow:
-$12.57M
1W Performance:
-8.89%
1M Performance:
-30.50%
6M Performance:
-56.35%
1Y Performance:
-65.88%
1-Day Range:
$0.39$0.4213
1-Week Range:
$0.39$0.473
52-Week Range:
$0.39$1.49
Aprea Therapeutics Inc Stock (APRE) Company Profile
Name
Aprea Therapeutics IncSector
HealthcareIndustry
BiotechnologyPhone
215-948-4119Address
3805 OLD EASTON ROAD, DOYLESTOWN, MA, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS